Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6615335 | 0.85 | MAPT (0.39) | AIMP2POLBMAPT | |
| SCHEMBL6609064 | 0.83 | DRD2 (0.60) | HTR1ADRD2 | |
| SCHEMBL6610101 | 0.69 | DRD2 (0.60) | HTR1ADRD2 | |
| SCHEMBL6608716 | 0.69 | DRD2 (0.55) | HTR1ADRD2 | |
| SCHEMBL9466855 | 0.69 | HTR1A (0.45) | HTR1A | |
| SCHEMBL6615339 | 0.69 | AIMP2 (0.38) | AIMP2POLBMAPT | |
| SCHEMBL7127651 | 0.69 | L3MBTL1 (0.61) | HTR1AHTR1DHTR1BMAPT | |
| SCHEMBL6609658 | 0.68 | DRD2 (0.69) | HTR1ADRD2 | |
| SCHEMBL6609724 | 0.68 | DRD2 (0.64) | HTR1ADRD2 | |
| SCHEMBL9183299 | 0.68 | HTR1A (0.58) | HTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149087-B1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-6596722-B2 | Serotonin reuptake inhibitors/HT3 receptor antagonists useful for treatment of depression, psychosis, anxiety disorders, panic disorder, obsessive compulsive disorder, and eating disorders | H. LUNDBECK A/S (DK) | 2003-07-22 | — | — | US | disclosed |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S | 2002-11-21 | — | — | US | disclosed |
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | DRD1, DRD2, H1-5 | HTR1A 51/4885HTR1D 23/4885HTR1B 53/4885 |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | DRD1, DRD2, H1-5 | HTR1A 51/4885HTR1D 23/4885HTR1B 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.